Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Panbela Therapeutics, Inc. | ex_99829.htm |
| EX-31.2 - EXHIBIT 31.2 - Panbela Therapeutics, Inc. | ex_99827.htm |
| EX-31.1 - EXHIBIT 31.1 - Panbela Therapeutics, Inc. | ex_99826.htm |
| 10-Q - FORM 10-Q - Panbela Therapeutics, Inc. | snbp20170930_10q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, David B. Kaysen, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
the Quarterly Report on Form 10-Q of Sun BioPharma, Inc. for the quarter ended September 30, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Sun BioPharma, Inc. |
Dated: November 14, 2017
|
/s/ David B. Kaysen |
|
|
David B. Kaysen |
|
|
President and Chief Executive Officer |
|
|
(Principal Executive Officer) |